Cargando…

Adverse drug events observed with 150 mg versus 300 mg secukinumab for the treatment of moderate to severe plaque psoriasis: A systematic review and meta-analysis

BACKGROUND: Secukinumab has been approved for the treatment of moderate to severe plaque psoriasis. However, safety measures concerning drug administration is vital during treatment. Understanding the right way to administer drugs is important to reduce any serious adverse drug event. In this analys...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Li, Yang, Hua, Chen, Qihong, Zhao, Jing
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer Health 2019
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6336633/ https://www.ncbi.nlm.nih.gov/pubmed/30633199 http://dx.doi.org/10.1097/MD.0000000000014042

Ejemplares similares

Premedication with pregabalin 150mg versus 300mg for postoperative pain relief after laparoscopic cholecystectomy
por: Singh, Tanveer, et al.
Publicado: (2020)

Secukinumab: A Review in Moderate to Severe Pediatric Plaque Psoriasis
por: Blair, Hannah A.
Publicado: (2021)

Cost effectiveness of ixekizumab versus secukinumab in the treatment of moderate-to-severe plaque psoriasis in Spain
por: Johansson, Erin, et al.
Publicado: (2018)

Treatment challenges in the management of moderate-to-severe plaque psoriasis – role of secukinumab
por: Malakouti, Mona, et al.
Publicado: (2016)

Correction to: Secukinumab: A Review in Moderate to Severe Pediatric Plaque Psoriasis
por: Blair, Hannah A.
Publicado: (2021)

Burden of Moderate-to-Severe Plaque Psoriasis and New Therapeutic Approaches (Secukinumab): An Italian Perspective
por: Mantovani, Lorenzo, et al.
Publicado: (2016)

Comparative efficacy of secukinumab against adalimumab and infliximab in patients with moderate-to-severe plaque psoriasis
por: Pan, Ran, et al.
Publicado: (2022)

Secukinumab 150/300 mg Provides Sustained Improvements in the Signs and Symptoms of Active Ankylosing Spondylitis: 3‐Year Results from the Phase 3 MEASURE 3 Study
por: Pavelka, Karel, et al.
Publicado: (2020)

Cost-Effectiveness of Secukinumab Versus Other Biologics in the Treatment of Moderate-to-Severe Plaque Psoriasis: The Chinese Healthcare System Perspective
por: Zhang, Jinsui, et al.
Publicado: (2023)

Secukinumab in the Treatment of Plaque Psoriasis in Patients with Malignancy
por: Gambardella, Alessio
Publicado: (2019)

Effectiveness and safety of secukinumab in patients with moderate-to-severe plaque psoriasis – a real life retrospective study
por: Galica, Katarzyna, et al.
Publicado: (2020)

Assessment of serum biomarkers in patients with plaque psoriasis on secukinumab
por: Morita, Akimichi, et al.
Publicado: (2020)

Efficacy of Secukinumab for Plaque Psoriasis in a Patient on Hemodialysis
por: Ikuma, Daiuske, et al.
Publicado: (2019)

Efficacy and Safety of Subcutaneous Secukinumab 150 mg with or Without Loading Regimen in Psoriatic Arthritis: Results from the FUTURE 4 Study
por: Kivitz, Alan J., et al.
Publicado: (2019)

Secukinumab is Superior to Ustekinumab in Clearing Skin in Patients with Moderate to Severe Plaque Psoriasis (16-Week CLARITY Results)
por: Bagel, Jerry, et al.
Publicado: (2018)

Efficacy and safety of secukinumab in Chinese patients with moderate-to-severe plaque psoriasis: a real-life cohort study
por: Zhao, Yan, et al.
Publicado: (2021)

Adverse drug events observed in patients with type 2 diabetes mellitus treated with 100 mg versus 300 mg canagliflozin: a systematic review and meta-analysis of published randomized controlled trials
por: Bundhun, Pravesh Kumar, et al.
Publicado: (2017)

Population Pharmacokinetic Modeling of Secukinumab in Patients With Moderate to Severe Psoriasis
por: Bruin, Gerard, et al.
Publicado: (2017)

Position Statement on Secukinumab in the Management of Plaque Psoriasis: The Malaysian Perspective
por: Johar, Asmah, et al.
Publicado: (2019)

Effects of secukinumab on metabolic and liver parameters in plaque psoriasis patients
por: Gerdes, S., et al.
Publicado: (2019)

Efficacy and Safety of Secukinumab in Patients with Plaque Psoriasis and Latent Tuberculosis
por: Ribero, Simone, et al.
Publicado: (2019)

Alopecia Areata After Initiation of Secukinumab Therapy for Plaque Psoriasis
por: Choi, Esther, et al.
Publicado: (2023)

Efficacy and Safety of Secukinumab 150 mg with and Without Loading Regimen in Ankylosing Spondylitis: 104-week Results from MEASURE 4 Study
por: Kivitz, Alan J., et al.
Publicado: (2018)

Efficacy and Safety of Secukinumab in Elderly Subjects with Moderate to Severe Plaque Psoriasis: A Pooled Analysis of Phase III Studies
por: Körber, Andreas, et al.
Publicado: (2018)

Secukinumab is Efficacious and Safe in Hispanic Patients with Moderate-to-Severe Plaque Psoriasis: Pooled Analysis of Four Phase 3 Trials
por: Adsit, Sandra, et al.
Publicado: (2017)

The Societal Economic Impact of Secukinumab in First-Line Treatment of Moderate to Severe Plaque Psoriasis in Germany: An Open-Cohort Simulation
por: Seddik, Ahmed H., et al.
Publicado: (2021)

Effectiveness and Safety of Secukinumab in Latin American Patients with Moderate to Severe Plaque Psoriasis: PURE Registry 12-Month Data
por: Papp, Kim A., et al.
Publicado: (2022)

Sustained Effectiveness of Secukinumab Across Different Body Regions in Patients with Moderate-to-Severe Plaque Psoriasis from the PURE Registry
por: Gooderham, Melinda, et al.
Publicado: (2022)

Efficacy and Safety of Secukinumab in Elderly Patients with Moderate to Severe Plaque-Type Psoriasis: Post-Hoc Analysis of the SUPREME Study
por: Talamonti, Marina, et al.
Publicado: (2023)

Clinical utility of secukinumab in moderate-to-severe scalp psoriasis: evidence to date
por: Kivelevitch, Dario, et al.
Publicado: (2019)

Efficacy and Safety of Secukinumab in Chronic Plaque Psoriasis and Psoriatic Arthritis Therapy
por: Gisondi, Paolo, et al.
Publicado: (2014)

Widespread Superficial Dermatophytosis in Patient on Secukinumab for Treatment of Chronic Plaque Psoriasis
por: Neema, Shekhar, et al.
Publicado: (2019)

Successful secukinumab treatment in focal segmental glomerulosclerosis associated with plaque psoriasis
por: Cao, Zhiqiang, et al.
Publicado: (2022)

Effects of adalimumab and secukinumab on comorbidities associated with metabolism in patients with plaque psoriasis
por: Zhang, Si, et al.
Publicado: (2022)

Erratum to: Secukinumab is Efficacious and Safe in Hispanic Patients with Moderate-to-Severe Plaque Psoriasis: Pooled Analysis of Four Phase 3 Trials
por: Adsit, Sandra, et al.
Publicado: (2017)

Efficacy, Safety, and Pharmacoeconomic Analysis of Adalimumab and Secukinumab for Moderate-to-Severe Plaque Psoriasis: A Single-Center, Real-World Study
por: Li, Gaojie, et al.
Publicado: (2022)

Treatment outcomes of secukinumab in adult patients with moderate‐to‐severe plaque psoriasis in China: A real‐world multicenter retrospective study
por: Ding, Yangfeng, et al.
Publicado: (2023)

Secukinumab demonstrates high efficacy and a favorable safety profile over 52 weeks in Chinese patients with moderate to severe plaque psoriasis
por: Cai, Lin, et al.
Publicado: (2020)

Efficacy of Risankizumab versus Secukinumab in Patients with Moderate-to-Severe Psoriasis: Subgroup Analysis from the IMMerge Study
por: Crowley, Jeffrey J., et al.
Publicado: (2022)

Long-term efficacy and safety of secukinumab 150 mg in ankylosing spondylitis: 5-year results from the phase III MEASURE 1 extension study
por: Baraliakos, Xenofon, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_hg9e0788tpc78jjnq304phc1i5